BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 11508859)

  • 1. The alpha,alpha-difluorinated phosphonate L-pSer-analogue: an accessible chemical tool for studying kinase-dependent signal transduction.
    Panigrahi K; Eggen M; Maeng JH; Shen Q; Berkowitz DB
    Chem Biol; 2009 Sep; 16(9):928-36. PubMed ID: 19778720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for allosteric effects on p53 oligomerization induced by phosphorylation.
    Muller P; Chan JM; Simoncik O; Fojta M; Lane DP; Hupp T; Vojtesek B
    Protein Sci; 2018 Feb; 27(2):523-530. PubMed ID: 29124793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.
    Pospísilová S; Brázda V; Kucharíková K; Luciani MG; Hupp TR; Skládal P; Palecek E; Vojtesek B
    Biochem J; 2004 Mar; 378(Pt 3):939-47. PubMed ID: 14640983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel system to investigate the phosphorylation of the p53 tumor suppressor protein by the protein kinase CK2.
    McKendrick L; Meek DW
    Cell Mol Biol Res; 1994; 40(5-6):555-61. PubMed ID: 7735330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody NF-09 specific for neurofilament protein NF-M.
    Dráberová E; Sulimenko V; Kukharskyy V; Dráber P
    Folia Biol (Praha); 1999; 45(4):163-5. PubMed ID: 10732731
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterization of protein kinase CK2 protein subunits and p53 in F9 teratocarcinoma cells in the absence and presence of cisplatin.
    Küpper M; Köster M; Schmidt-Spaniol I; Wagner-Gillen I; Issinger OG
    Cell Mol Biol Res; 1994; 40(5-6):587-92. PubMed ID: 7735333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific DNA binding by p53 is independent of mutation at serine 389, the casein kinase II site.
    Rolley N; Milner J
    Oncogene; 1994 Oct; 9(10):3067-70. PubMed ID: 8084615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of phosphorylatable monoclonal antibody CC49 with a casein kinase II recognition site.
    Lin L; Gillies SD; Schlom J; Pestka S
    Anticancer Res; 1998; 18(6A):3971-8. PubMed ID: 9891433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New monoclonal antibodies recognizing p53 protein phosphorylated by casein kinase II at serine 392.
    Pospísilová S; Kanková K; Svitáková M; Nenutil R; Vojtesek B
    Folia Biol (Praha); 2001; 47(4):148-51. PubMed ID: 11508859
    [No Abstract]   [Full Text] [Related]  

  • 10. The development and use of phospho-specific antibodies to study protein phosphorylation.
    Blaydes JP; Vojtesek B; Bloomberg GB; Hupp TR
    Methods Mol Biol; 2000; 99():177-89. PubMed ID: 10909085
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant chimeric monoclonal antibodies.
    Morrison SL; Schlom J
    Important Adv Oncol; 1990; ():3-18. PubMed ID: 2182522
    [No Abstract]   [Full Text] [Related]  

  • 12. Identifying protein kinase substrates: hunting for the organ-grinder's monkeys.
    Berwick DC; Tavaré JM
    Trends Biochem Sci; 2004 May; 29(5):227-32. PubMed ID: 15130558
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.